The Co-Occurrence of Alzheimer's Disease and Huntington's Disease: A Neuropathological Study of 15 Elderly Huntington's Disease Subjects

Journal of Huntington's Disease

Volumn 3, Issue 2, 2014, Pages 209-217

  Davis, Marie Y ^a,b   Keene, C Dirk ^a   Jayadev, Suman ^a   Bird, Thomas ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; dementia; Huntington's disease; parkinsonism

Indexed keywords

AMYLOID BETA PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; BRAIN TISSUE; BRAIN WEIGHT; CAG REPEAT; CELL NUCLEUS INCLUSION BODY; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; INCIDENCE; LEWY BODY; MALE; MOTOR PERFORMANCE; NEUROFIBRILLARY TANGLE; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PROBLEM SOLVING; SUBSTANTIA NIGRA; VERBAL MEMORY; WECHSLER MEMORY SCALE; WIDE RANGE ACHIEVEMENT TEST; AGING; BRAIN; MIDDLE AGED; PARKINSON DISEASE; PARKINSONISM; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ALZHEIMER'S DISEASE; DEMENTIA; HUNTINGTON'S DISEASE; PARKINSONISM;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN; DEMENTIA; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES;

EID: 84907219653     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140111     Document Type: Article

References (37)

1. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, Investigators T-H. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12:637-49.
2. Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Durr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry. 2012;83:687-94.
3. Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC. The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation.Mov Disord. 2014;29:673-83.
4. Salmon DP, Kwo-on-Yuen PF, Heindel WC, Butters N, Thal LJ. Differentiation of Alzheimer's disease and Huntington's disease with the Dementia Rating Scale. Arch Neurol. 1989;46:1204-8.
5. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44:559-77.
6. Myers RH, Sax DS, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, White RF, Martin JB. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry. 1985;48:530-4.
7. Jellinger KA. Alzheimer-type lesions in Huntington's disease. J Neural Transm. 1998;105:787-99.
8. McIntosh GC, Jameson HD, Markesbery WR. Huntington disease associated with Alzheimer disease. Ann Neurol. 1978;3:545-8.
9. Reyes MG, Gibbons S. Dementia of the Alzheimer's type and Huntington's disease. Neurology. 1985;35:273-7.
10. Moss RJ, Mastri AR, Schut LJ. The coexistence and differentiation of late onset Huntington's disease and Alzheimer's disease. A case report and review of the literature. J Am Geriatr Soc. 1988;36:237-41.
11. Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013;84:1156-60.
12. Lipe H, Bird T. Late onset Huntington Disease: Clinical and genetic characteristics of 34 cases. J Neurol Sci. 2009;276:159-62.
13. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis. Mov Disord. 2012;27:1083-91.
14. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137-52.
15. Plassman BL, Langa KM, Fisher GG, Heeringa SG,Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB. Prevalence of dementia in the United States: The aging, demographics, and memory study. Neuroepidemiology. 2007;29:125-32.
16. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on A, Alzheimer's A. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol. 2012;123: 1-11.
17. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1-13.
18. Thal DR, Rub U, Orantes M, Braak H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-800.
19. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 1991;82:239-59.
20. Mirra SS, Heyman A,McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L, The Consortium to. Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-86.
21. Paulsen JS. Cognitive impairment in Huntington disease: Diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11:474-83.
22. Peavy GM, JacobsonMW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee JC, Corey-Bloom J. Cognitive and functional decline in Huntington's disease: Dementia criteria revisited. Mov Disord. 2010;25:1163-9.
23. Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, Snowden J, Thompson J, Esmonde T, Gentry R, Moore JW, Bodner T, Consortium N-H. Profile of cognitive progression in early Huntington's disease. Neurology. 2003;61: 1702-6.
24. Rosser AE, Hodges JR. The Dementia Rating Scale in Alzheimer's disease, Huntington's disease and progressive supranuclear palsy. J Neurol. 1994;241:531-6.
25. Erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, Leahy M, Montine T, Kaye J. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology. 2009;72:354-60.
26. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, KukullW, Morris JC. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026-36.
27. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry. 1998;65:577-9.
28. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry. 2000;68:238-41.
29. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol. 1990;27:357-65.
30. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol. 2008;67:1159-65.
31. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, FeidenW, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130-3.
32. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602-11.
33. Vonsattel JP KC, Del Pilar Amaya M. Neuropathology of Hungtington's Disease. In: Duyckaerts C LI, editors. Handbook of Clinical Neurology-Dementias. Elsevier. 2008; p. 599-618.
34. Dupuis L. Mitochondrial quality control in neurodegenerative diseases. Biochimie. 2014;100:177-83.
35. Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther. 2012;342:619-30.
36. de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord. 2004;19:1516-8.
37. Bird TD, Lipe HP, Steinbart EJ. Geriatric neurogenetics: Oxymoron or reality? Arch Neurol. 2008;65:537-9.